Michael J. Hassett, MD, MPH

Men's breast cancer awareness is crucial as it often goes unrecognized, leading to advanced stages at diagnosis, Michael Hassett, MD, explains.

Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition in personalized therapy strategies.

Michael Hassett, MD, MPH, discusses the rise of oral therapeutics in breast cancer care, emphasizing patient support, education, and overcoming financial barriers for better outcomes.

Despite its potential, incorporating new treatments like T-DXd into a first-line setting faces several barriers, explains Michael Hassett, MD, MPH, chief quality officer at Dana-Farber Cancer Institute in Boston.

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum.

Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.